United States - English - NLM (National Library of Medicine)

trigen laboratories llc - pyridostigmine bromide (unii: kvi301na53) (pyridostigmine - unii:19qm69hh21) - pyridostigmine bromide oral solution is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. care should be observed in the use of atropine for counteracting side effects, as discussed below.

United States - English - NLM (National Library of Medicine)

trigen laboratories, llc - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7) - hydrocodone bitartrate 2.5 mg

United States - English - NLM (National Library of Medicine)

trigen laboratories, llc - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 2 mg - ropinirole extended-release tablets are indicated for the treatment of parkinson’s disease.  ropinirole extended-release tablets are contraindicated in patients known to have a hypersensitivity/allergic reaction including urticaria, angioedema, rash, pruritus) to ropinirole or any of the excipients. risk summary   there are no adequate data on the developmental risk associated with the use of ropinirole extended-release tablets in pregnant women. in animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the maximum recommended human dose (mrhd) for parkinson’s disease. ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. in pregnant rabbits, ropinirole potentiated the teratogenic effects of l-dopa when these drugs were administered in combination [see data] . in the u.s. general popul

United States - English - NLM (National Library of Medicine)

trigen laboratories, llc - sodium phenylacetate (unii: 48n6u1781g) (phenylacetic acid - unii:er5i1w795a), sodium benzoate (unii: oj245fe5eu) (benzoic acid - unii:8skn0b0mim) - sodium phenylacetate 100 mg in 1 ml - sodium phenylacetate and sodium benzoate injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. during acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see warnings and precautions (5) ]. none. pregnancy category c. animal reproduction studies have not been conducted with sodium phenylacetate and sodium benzoate injection, 10%/10%. it is not known whether sodium phenylacetate and sodium benzoate injection, 10%/10% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. thus, sodium phenylacetate and sodium benzoate injection, 10%/10% should be given to a pregnant woman only if clearly needed. it is not known whether sodium phenylacetate, sodium benzoate, or their

United States - English - NLM (National Library of Medicine)

trigen laboratories, llc - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol gel is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding [see warning and precautions (5.2)] - breast cancer or history of breast cancer [see warning and precautions (5.2)] - estrogen-dependent neoplasia [see warning and precautions (5.2)] - active dvt, pe, or history of these conditions [see warning and precautions (5.1)] - active arterial thromboembolic disease (e.g. stroke and mi), or a history of these conditions [see warning and precautions (5.1)] - known anaphylactic reaction, angioedema, or hypersensitivity to estradiol gel - hepatic impairment or disease - protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders risk summary estradiol gel is not indicated for use in pregnant women. there are no data with the use of estradiol gel in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-redu

United States - English - NLM (National Library of Medicine)

trigen laboratories, llc - nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l), nitrofurantoin monohydrate (unii: e1qi2cqq1i) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin capsules, usp (monohydrate/macrocrystals) are indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of escherichia coli or staphylococcus saprophyticus . nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules, usp (monohydrate/macrocrystals)   and other antibacterial drugs, nitrofurantoin capsules, usp (monohydrate/macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the

United States - English - NLM (National Library of Medicine)

carilion materials management - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 10 mg - aripiprazole is indicated for the treatment of: •schizophrenia [see clinical studies (14.1)] additional pediatric use information is approved for otsuka america pharmaceutical, inc.’s abilify® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)]. teratogenic effects there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aripiprazole during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. neonates exposed to antipsychotic drugs (including aripiprazole) duri

Australia - English - Department of Health (Therapeutic Goods Administration)

astley dolphin australia pty ltd - 9950 - disinfectant, hospital grade - other therapeutic

Australia - English - Department of Health (Therapeutic Goods Administration)

astley dolphin australia pty ltd - 9950 - disinfectant, hospital grade - other therapeutic

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ceva animal health pty ltd - polihexanide; benzalkonium chloride; didecyl dimethyl ammonium chloride - soluble concentrate - polihexanide guanidine active 1.0 g/l; benzalkonium chloride ammonium-quaternary active 50.0 g/l; didecyl dimethyl ammonium chloride ammonium-quaternary active 75.0 g/l - disinfectant - animal houses & living areas (domestic) | veterinary hospital | bird cage | kennels - bacteria | bacterial spore | fungus | virus | fungal leaf spots | fungi | fungus diseases | leaf spot diseases | leaf spots